Rosehip Extracts can Improve Breast Cancer Outcomes, Estrogen Therapy can Lower Risk Postmenopause
In what could be a major breakthrough, a new study has found that rosehip extracts can improve treatment outcomes of most severe type of breast cancer, the type triple-negative type.
The new study carried out by researchers at North Carolina Agricultural and Technical State University showed that application of rosehip extract in high concentrations to triple-negative breast cancer tissue cultures showed a marked increase in efficiency of breast cancer drug doxorubicin and also decreased cell multiplication and movement by 50 percent.
"My hope is that our studies in tissue cultures, along with future studies in animal models, will lead to rosehip being recommended as a preventative measure in breast cancer or as an addition to current cancer treatment," Patrick Martin, the study's lead said.
Triple-negative breast cancer does not respond well to treatment and is more aggressive than other types. Patients have higher rates of reoccurrence and mortality.
Researchers hope that rosehip extract can be made as a tablet for daily consumption to prevent breast cancer or lower severity of the disease to achieve cure.
Another significant development in breast cancer research is the finding of increased cancer risk with combined estrogen-progesterone therapies. A study conducted by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Torrance also found that estrogen alone can reduce overall risk of cancer incidence in postmenopausal women.
